Skip to main content
TipRanks
Go Ultimate75% OFF

Cyfuse Biomedical K.K. (4892) AI Stock Analysis

0 Followers
JP:4892

Cyfuse Biomedical K.K.

(TSE/TYO:4892)

Select Model
Rating:37Underperform
Price Target:JPY 468.00â–¼(-8.95% Downside)
Action:downgraded
Date:11/07/26

The stock scores at the absolute bottom of the range, driven by a convergence of severe fundamental and market risks. The primary concern is the company's precarious financial state, marked by deep net losses and significant cash burn that threaten its sustainability. This is compounded by a bearish technical trend with the price trading below all key moving averages and deeply oversold momentum. The negative P/E ratio further confirms the lack of earnings power. The combination of weak financials and negative market sentiment leaves no positive catalysts to offset the risks.

Positive Factors
Revenue reboundThe sharp 2025 revenue recovery shows that the company can generate materially higher sales when product demand and commercialization improve. If this growth is sustained, greater scale could help absorb fixed costs, support investment in the platform, and improve future operating leverage.
Negative Factors
Persistent unprofitabilityExtremely negative operating and net margins indicate that the current revenue base is not yet sufficient to support the cost structure. Persistent losses reduce retained capital, make self-funded expansion difficult, and leave future earnings dependent on substantial improvement in scale, pricing, or operating efficiency.

Cyfuse Biomedical K.K. (4892) vs. iShares MSCI Japan ETF (EWJ)

-20%-10%0%10%20%30%40%JP:4892-10.61%EWJ+16.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 5.19B
Dividend Yield
―
Average Volume (3M)
50.01K
Price to Earnings (P/E)
-6.3
Beta (1Y)
0.46
Revenue Growth
364.72%
EPS Growth
18.43%
Country
Japan
Employees
23
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Cyfuse Biomedical K.K. Business Overview & Revenue Model

Company Description

Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic...

Cyfuse Biomedical K.K. Financial Statement Overview

Summary

Financial health is critically weak. Despite a 253% revenue surge, the company is deeply unprofitable with a -330% net margin and has negative operating and free cash flow. The moderate debt-to-equity ratio of 0.48 provides only a thin cushion against persistent cash burn and declining equity.

Income Statement

25Negative

Balance Sheet

45Neutral

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue305.90M231.00M54.45M61.11M374.48M708.25M
Gross Profit145.27M78.40M1.56M-378.00K223.93M568.20M
EBITDA-743.38M-792.68M-860.12M-659.31M-370.81M89.07M
Net Income-795.91M-763.84M-872.24M-589.21M-473.96M142.91M
Balance Sheet
Total Assets3.93B4.27B3.52B4.21B4.82B2.65B
Cash, Cash Equivalents and Short-Term Investments3.39B3.73B3.05B3.87B4.44B2.41B
Total Debt1.23B1.31B852.80M913.00M857.79M569.06M
Total Liabilities1.30B1.51B975.60M1.01B1.05B746.12M
Stockholders Equity2.62B2.76B2.54B3.20B3.77B1.90B
Cash Flow
Free Cash Flow0-581.93M-768.16M-581.77M-631.87M161.54M
Operating Cash Flow0-534.79M-760.55M-562.30M-403.60M161.54M
Investing Cash Flow0-397.56M-8.64M-19.47M-430.67M-50.58M
Financing Cash Flow01.26B-52.01M18.24M2.66B229.21M

Cyfuse Biomedical K.K. Technical Analysis

Technical Analysis SentimentNegative
Last Price514.00

Price Trends

50DMA601.64Negative
100DMA570.23Negative
200DMA600.36Negative

Market Momentum

MACD-23.72Positive
RSI34.89Neutral
STOCH41.18Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4892, the sentiment is Negative. The current price of 514.00 is below the 20-day moving average (MA) of 556.20, below the 50-day MA of 601.64, and below the 200-day MA of 600.36, indicating a bearish trend. The MACD of -23.72 indicates Positive momentum. The RSI at 34.89 is Neutral, neither overbought nor oversold. The STOCH value of 41.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4892.

Cyfuse Biomedical K.K. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4892 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:7079JP:707980OutperformJPY 6.09B0.93―3.75%-8.78%0.01%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4539JP:453947NeutralJPY 5.47B-11.24―3.30%0.31%-194.72%
JP:4582JP:458243NeutralJPY 5.95B-0.69――-30.58%6.93%
JP:4883JP:488343NeutralJPY 3.48B-1.41―――25.34%
JP:4597JP:459739UnderperformJPY 6.82B-7.89-53.06%―109.82%61.98%
JP:4892JP:489237UnderperformJPY 5.19B-6.28――364.72%18.43%

* Healthcare Sector Average

Performance Comparison

-50%0%50%JP:4892JP:4597JP:4539JP:4582JP:4883JP:7079Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4892 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4892Cyfuse Biomedical K.K.514.00-67.00-11.53%
JP:4597Solasia Pharma KK25.00-8.00-24.24%
JP:4539Nippon Chemiphar Co., Ltd.1515.0034.182.31%
JP:4582Symbio Pharmaceuticals Limited59.00-47.00-44.34%
JP:4883Modalis Therapeutics Corporation30.00-37.00-55.22%
JP:7079WDB coco Co., Ltd.2531.0030.451.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026